Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today?
Portfolio Pulse from Vandana Singh
Voyager Therapeutics Inc (VYGR) stock soared after announcing a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NVS), for gene therapies targeting Huntington's disease and spinal muscular atrophy. Voyager will license its TRACER capsids to Novartis and receive $100 million upfront, including a $20 million equity purchase, with potential for $1.2 billion in milestones and royalties. Novartis will handle development and commercialization, while Voyager focuses on preclinical advancement. VYGR shares jumped 36% to $11.48.
January 02, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis AG's subsidiary entered into a collaboration with Voyager Therapeutics, gaining access to novel gene therapy technology, which could enhance its neurological disease treatment portfolio.
The deal with Voyager allows Novartis to expand its gene therapy portfolio, which could have positive implications for its stock. However, as a larger company, the impact on Novartis' stock may be less pronounced compared to Voyager.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Voyager Therapeutics' stock surged due to a significant collaboration with Novartis for gene therapy development, receiving a substantial upfront payment and potential future milestones.
The collaboration with Novartis is a strong validation of Voyager's technology and provides significant financial resources, which is likely to be viewed positively by investors and could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100